argenx SE
ARGNF
Get informed when a big investor buys or sells
+ FollowMarket Cap$57.16B
Close$
Share Statistics
| Market cap | $57.16 Billion |
|---|---|
| Enterprise Value | $53.68 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 25.29% |
|---|---|
| Return on Assets | 21.22% |
| Return on Invested Capital | 25.00% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 9.48 |
| Enterprise Value to EBIT | 25.39 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Argen X SE
1,599 employees
CEO: Tim Van Hauwermeiren argenx SE is a biotechnology firm dedicated to advancing innovative treatments for autoimmune conditions across key global markets, including the United States, several European nations (the Netherlands, Belgium, Switzerland, Germany, Fr...